There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Lisata Therapeutics Inc (LSTA) advances its pipeline with promising trial results for certepatide, despite facing financial ...

The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation. Lisata Therapeutics Inc ...

Lisata is also partnering with Valo Therapeutics (ValoTx) to investigate the benefits ... This was primarily due to a reduction in expenses associated with the Phase 2b ASCEND trial which completed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...

Portland Police responded to a stabbing call in the 3900 block of North Vancouver Avenue early Wednesday morning. Officers ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...